论文部分内容阅读
虽然从未有人对长效β受体激动剂治疗哮喘的疗效产生过质疑,但关于其安全性却在上市后十几年的时间里都未进行过系统的评价。为了更好的开发和使用此类药物,必须进行一次大规模的安全性评价研究。
Although no one has questioned the efficacy of long-acting beta-agonists in the treatment of asthma, its safety has not been systematically evaluated more than a decade after its release. In order to better develop and use these drugs, we must conduct a large-scale safety evaluation study.